Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
06/2005
06/01/2005EP1535891A1 Remedy
06/01/2005EP1535630A1 Preventive for the onset of diabetes
06/01/2005EP1535512A1 DISEASE MODEL ANIMAL CARRYING FOREIGN PPARa GENE TRANSFERRED THEREINTO AND USE THEREOF
06/01/2005EP1535067A2 PAPSSs AS MODIFIERS OF THE AXIN PATHWAY AND METHODS OF USE
06/01/2005EP1535065A2 Neuroprotective synergy of erythropoietin and insulin-like growth factor
06/01/2005EP1534847A1 Retroviral vector and stable packaging cell lines
06/01/2005EP1534807A1 A process for decreasing the amount of cholesterol in a marine oil using a volatile working fluid
06/01/2005EP1534753A2 Antibody peg positional isomers, compositions comprising same, and use thereof
06/01/2005EP1534728A2 Antisense modulation of glucocorticoid receptor expression
06/01/2005EP1534725A2 Compounds and methods for inhibiting selectin-mediated function
06/01/2005EP1534720A1 Mitochondrially targeted antioxidants
06/01/2005EP1534708A2 Purine derivatives and their use as antiproliferative agents
06/01/2005EP1534707A1 Substituted 2,4-dihydro-pyrrolo (3, 4-b) -quinolin-9-one derivatives useful as phosphodiesterase inhibitors
06/01/2005EP1534706A1 Furanthiazole derivatives as heparanase inhibitors
06/01/2005EP1534693A2 1, 3-diamino-2-hydroxypropane prodrug derivatives
06/01/2005EP1534687A1 Pyrimidine compounds
06/01/2005EP1534677A1 Piperidine derivatives and their use as selective inhibitors of mip-1alpha binding to its receptor ccr1
06/01/2005EP1534676A1 Piperidinetriol derivatives as inhibitors of glycosylceramide synthase
06/01/2005EP1534668A1 Crystalline solid form of (2s-5z)-2-amino-7-(ethanimidoylamino)-2-methylhept-5-enoic acid
06/01/2005EP1534512A1 Coated particles, methods of making and using
06/01/2005EP1534391A1 Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders
06/01/2005EP1534389A2 Pyrazolopyrimidines as kinase inhibitors
06/01/2005EP1534338A1 Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer
06/01/2005EP1534332A2 Antibodies and uses thereof
06/01/2005EP1534331A2 Membrane associated tumor endothelium markers
06/01/2005EP1534322A1 Minibrain homologous proteins involved in the regulation of energy homeostasis
06/01/2005EP1534321A1 Methods of use of compounds with preptin function
06/01/2005EP1534302A2 Arginine silicate inositol complex and use thereof
06/01/2005EP1534300A2 3, 10, and 12a substituted tetracycline compounds
06/01/2005EP1534298A2 Novel anticholesterol compositions and method for using same
06/01/2005EP1534296A1 Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
06/01/2005EP1534290A2 Novel inhibitors of kinases
06/01/2005EP1534281A1 N-sulfonylpiperidines as metalloproteinase inhibitors (tace)
06/01/2005EP1534277A1 Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
06/01/2005EP1534275A1 Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
06/01/2005EP1534271A1 Antitumor compound and therapeutic uses thereof
06/01/2005EP1534270A2 Carvedilol phosphate salts and/or solvates thereof, correspondinq compositions, and/or methods of treatment
06/01/2005EP1534264A2 Compounds that modulate the activity of ptp-1b and tc-ptp
06/01/2005EP1534259A2 Sulfonamides as potassium channel blockers
06/01/2005EP1534250A2 Electrospun amorphous pharmaceutical compositions
06/01/2005EP1453820B1 Substituted 6h-dibenzo[c,h]chromenes as estrogenic agents
06/01/2005EP1448794A4 Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis
06/01/2005EP1423002A4 Use of cross-linked, covalently bound urokinase plasminogen activator (scupa)-urokinase plasminogen activator receptor (supar) complex as a fibrinolytic agent
06/01/2005EP1404330B1 Substituted 8-arylquinoline pde4 inhibitors
06/01/2005EP1347760B1 Nmda receptor agonist pharmaceutical compositions
06/01/2005EP1345902B1 Substituted heterocyclo-norbornylamine derivatives, method for producing the same, their use as medicament or diagnostic agent and medicament containing the same
06/01/2005EP1280526B1 Use of 2-iminobiotin for the manufacture of a medicament for the prevention and/or treatment, in newborn babies, of the effects of complications during childbirth
06/01/2005EP1268465B1 Triarylimidazole derivatives as cytokine inhibitors
06/01/2005EP1265614B1 Novel galenical form for oral administration with prolonged release of molsidomine
06/01/2005EP1254136A4 FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF
06/01/2005EP1233951B1 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
06/01/2005EP1178977B1 Ion channel modulating agents
06/01/2005EP1115695B1 (r)-chiral halogenated 1-substitutedamino-(n+1)-alkanols useful for inhibiting cholesteryl ester transfer protein activity
06/01/2005EP1095015B1 Sulfonylamino carboxylic acid n-arylamides as guanylate cyclase activators
06/01/2005EP1062210B1 1,2-diazepane derivatives as interleukin-1beta converting enzyme inhibitors
06/01/2005EP1042460B1 Brain or heart cyclic nucleotide gated ion channel compounds and uses thereof
06/01/2005EP1003744B1 4-AMINOPYRROLE(3,2-d) PYRIMIDINES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS
06/01/2005CN1622946A Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
06/01/2005CN1622945A Thiazolidinedione derivatives and pharmaceutical composition comprising the same
06/01/2005CN1622938A 方法 Method
06/01/2005CN1622937A Process for the manufacture of HMG-coa reductase inhibitors
06/01/2005CN1622936A Process for the preparation of high purity perindopril and intermediates useful in the synthesis
06/01/2005CN1622830A Peptide-based compounds
06/01/2005CN1622827A Thrombin derived peptides for promoting cardiac tissue repair
06/01/2005CN1622809A Orodispersible pharmaceutical composition comprising ivabradine
06/01/2005CN1621404A Drug and method for regulating cholesterol and triglyceride
06/01/2005CN1621094A Gene transfer for regulating smooth muscle tone
06/01/2005CN1621072A Ischemic cerebral vascular disease treating medicine
06/01/2005CN1621068A Quick effective heart rescuing pills
06/01/2005CN1204247C Recombined adenovirus and its use in curing myocardial ischemia
06/01/2005CN1204138C Pyrazolo [4, 3-d] pyrimidine derivs.
06/01/2005CN1204134C Sulfamine-substituted benzodihydopyran, preparation method, use as medicine or diagnostic reagent and medicine containing same
06/01/2005CN1203891C Medicine for treating coronary heart disease and its preparation method
06/01/2005CN1203890C Medicine for treating and preventing hypertension and hyperlipemia and its preparation
06/01/2005CN1203886C Medicine for treating cardiovascular diseases and its preparing method
06/01/2005CN1203880C Chinese patent medicine for treating hypotension and preparing method thereof
06/01/2005CN1203877C Chinese medicine preparation for treating hemorrhoidal bleeding and its preparing method
06/01/2005CN1203861C Cerebrovascular regeneration/reconstruction promoters and nerve tissue secondary degeneration inhibitors comprising ginsenoside Rb1
06/01/2005CN1203855C Pharmaceutical solutions for levosimendan
06/01/2005CN1203853C Special ingredient extract of tetrandra root and its use
06/01/2005CN1203852C Valdecoxib compositions
06/01/2005CN1203851C Use of inhibitor produced or released by reactive oxygen metablite in producing pharmaceutical
06/01/2005CN1203844C Solid themoformable pharmaceutical composition for the controlled release of ivabradine
05/2005
05/31/2005US6900353 Cyclopentyl sulfonamide derivatives
05/31/2005US6900344 Method of preparing alkylated salicylamides via a dicarboxylate intermediate
05/31/2005US6900338 Scavenger compounds
05/31/2005US6900329 MCH antagonists and their use in the treatment of obesity
05/31/2005US6900318 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor
05/31/2005US6900309 Aminocarbonylation reaction of a adenosine compound containing purine base and pentofuranosyl sugar and a leaving group at 2 position of purine ring, with an amine compound in presence of carbon monoxide and suitable coupling catalyst
05/31/2005US6900244 Controlling lipid, cholesterol metabolism; anticholesterol agents
05/31/2005US6900243 Phenylheteroalkylamine derivatives
05/31/2005US6900234 Hypotensive agents; congestive heart failure; using mixture of enzyme inhibitors of renin, angiotensin converting enzyme and angiotensin antagonist
05/31/2005US6900232 For therapy of tumor metastasis, solid tumor growth (neoplasia), osteoporosis, Paget's disease, humoral hypercalcemia of malignancy, osteopenia, angiogenesis, including tumor angiogenesis and lymphangiogenesis
05/31/2005US6900231 Aminopyridyl-substituted phenyl acetamides as protease inhibitors
05/31/2005US6900226 Quinoline and quinazoline derivatives; prophylaxis or treatment of arthritis, cardiovascular diseases, diabetes, renal failure and particularly eating disorders and obesity.
05/31/2005US6900222 Relaxant drugs; antiulcer agents
05/31/2005US6900221 Crystalline polymorph of erlotinib hydrochloride; synthesis; treating cancer
05/31/2005US6900219 ABCA-1 elevating compounds
05/31/2005US6900218 Reducing oxidation stresses; central nervous system disorders; antiinflammatory agents
05/31/2005US6900216 Psychological disorders; antidepressants; brain diosrders; anticonvulsants
1 ... 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 ... 1595